FDA decision means Pfizer boosters for healthcare workers: 5 things to know

(J. Harris: A sixth thing to know would be what to do if your prior vaccinations are JNJ or Moderna. Wait?  How long?)

From THE ATLANTIC:(a short very readable explanation of the value of vaccination that even your hard-headed quasi-intellectual daughter might understand is she would just read it. Read it and then send it to her. J. Harris)

No, Vaccinated People Are Not ‘Just as Likely’ to Spread the Coronavirus as Unvaccinated People

”…To spread the coronavirus, you have to have the coronavirus. And vaccinated people are far less likely to have the coronavirus—period. …Among the unvaccinated, the virus travels unhindered on a highway with multiple off-ramps and refueling stations. In the vaccinated, it gets lost in a maze of dead-end streets and cul-de-sacs. Every so often, it pieces together an escape route, but in most scenarios, it finds itself cut off, and its journey ends. It can go no further.

US likely to miss big winter COVID-19 surge, analyst models predict

Public Health Law after Covid-19

”…Courts have historically been deferential to health orders, especially during disease outbreaks…”

Mask Wars

(J. Harris: Historical graphic)

QUACK QUACK QUACK: America’s Frontline Doctors Face Long Overdue Medical and Legal Censure

(J. Harris: This is a well-written and referenced expose of fraud as well as the  murder of many gullible patients.)

COVID-19 Testing Moves Out of the Clinic and Into the Home

”…Testing, 1, 2, 3, Repeat

When a test is about as good as a coin toss, it’s not useful as a one-off, such as testing people before allowing them to enter a theater or a restaurant,…

But although rapid antigen tests aren’t as sensitive as PCR, their speed and lower cost make it easier to conduct serial testing, which improves the chance of detecting infection as viral loads increase. Using the tests in “closed environments” where people are tested regularly, such as in schools, would likely be a better application…They’re not as accurate as the lab-based PCRs, but if you do serial testing, they’re pretty accurate…you will eventually catch [positive] people…”

(J. Harris: I had trouble following this article — off day?)


PEDIATRIC VACCINATION DATA Pfizer and BioNTech on September 20 announced positive results from a Phase 2/3 trial of their SARS-CoV-2 vaccine in children aged 5 to 11 years. The researchers found that a 2-dose regimen of 10µg doses administered 21 days apart demonstrated a favorable safety profile and robust neutralizing antibody response. The findings—which are neither published nor peer-reviewed—are a crucial step toward a SARS-CoV-2 vaccine becoming available for younger children, and the companies expect to submit an application to the US FDA for the vaccine’s authorization for that age group by the end of September. US regulators have issued warnings to the general public to wait for authorization before seeking vaccination for younger children, as the full adult dose of 30µg may put children at a higher risk for adverse side effects, including myocarditis.

The trial included nearly 2,300 children, and two-thirds of them in the vaccine group. The vaccinated children also were compared with a separate cohort of 16-25-year-old individuals who received the full adult course of the vaccine (2 doses of 30µg). The trial found that the neutralizing antibody response was similar between both vaccinated groups, with the neutralizing antibody levels within 5% of each other. Both groups also experienced similar post-vaccination adverse events.

Results from another study evaluating the Sinopharm SARS-CoV-2 vaccine in children were published on September 15 in The Lancet Infectious Diseases. The Phase 1/2 trial examined the safety and immunogenicity of the vaccine in a cohort of children aged 3-17 years, with participants broken into several age groups (3-5, 6-12, and 13-17 years) and dosing groups (0 [control], 2µg, 4µg, and 8µg). Three (3) doses of each vaccine dosage or placebo were administered 28 days apart. All adverse events were categorized as mild or moderate severity, but the article does not report on serious adverse events. The study concluded that children who received the vaccine had robust immune responses and similar levels of neutralizing antibodies to those observed in older vaccine recipients. The study recommended a 2-shot 4µg dose regimen for future Phase 3 trials. Additional data are being collected through a Phase 3 trial currently taking place in the UAE. 


It is better to keep your mouth closed and let people think you are a fool than to open it and remove all doubt.   Mark Twain


GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s